Gilead's coronavirus treatment remdesivir to cost $3,120 per U.S. patient with private insurance

Gilead Sciences announced its pricing plans in preparation for it to begin charging for the drug in July. The company has been donating doses to the U.S. government for distribution since it received emergency use authorization in May. The drugmaker said it will sell remdesivir for $390 per vial to governments “of developed countries” around the world, and the price for U.S. private insurance companies will stand at $520 per vial.